These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37890355)

  • 21. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
    Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
    J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
    Stuver R; Geller S
    Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
    J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
    Berg S; Villasenor-Park J; Haun P; Kim EJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycosis Fungoides and Sezary Syndrome.
    Foss FM; Girardi M
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous T-cell lymphoma: practical recommendations to enhance clinical practice.
    Howles A; Scarisbrick J
    Br J Hosp Med (Lond); 2021 Mar; 82(3):1-6. PubMed ID: 33792384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
    Kim YH
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):303-312. PubMed ID: 34889422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycosis fungoides and Sézary syndrome - Review and outlook.
    Latzka J; Trautinger F
    J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
    Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
    Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
    Mehta-Shah N; Horwitz SM; Ansell S; Ai WZ; Barnes J; Barta SK; Clemens MW; Dogan A; Fisher K; Goodman AM; Goyal G; Guitart J; Halwani A; Haverkos BM; Hoppe RT; Jacobsen E; Jagadeesh D; Lunning MA; Mehta A; Olsen EA; Pro B; Rajguru SA; Shanbhag S; Shaver A; Shustov A; Sokol L; Torka P; Torres-Cabala C; Wilcox R; William BM; Zain J; Dwyer MA; Sundar H; Kim YH
    J Natl Compr Canc Netw; 2020 May; 18(5):522-536. PubMed ID: 32380458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
    Kim YH; Willemze R; Pimpinelli N; Whittaker S; Olsen EA; Ranki A; Dummer R; Hoppe RT;
    Blood; 2007 Jul; 110(2):479-84. PubMed ID: 17339420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.